Since its formation, Bespak®, the specialist inhalation contract development and manufacturing organisation (CDMO), has been driven by a singular goal: to be the trusted long-term innovation partner and sustainability leader in the transition to low Global Warming Potential (GWP) propellants for pressurised Metered Dose Inhalers (pMDIs).
Bespak’s commitment has resulted in the achievement of several key milestones, including:
Supporting the commercial-scale manufacture of the first low carbon pMDI
Completing its first life cycle assessment (LCA) on the industry trusted BK357 valve
Advancing innovation-led design and development through computational modelling and AI simulation
In our latest eBook in Drug Development & Delivery, we explore these achievements and more, examining how Bespak’s expertise, partnerships and manufacturing capabilities are helping to accelerate the transition to low carbon pMDIs. The eBook also highlights the company’s broader environmental strategy and its role in shaping a more sustainable industry while maintaining patient access to life-saving medicines.
